Industry analysts project that the GLP-1 market will surpass $150 billion by 2030, driven not only by diabetes management but increasingly by the approval of these drugs for obesity and cardiovascular indications. This massive market expansion presents a golden opportunity for peptide suppliers and CDMOs. The GLP-1 Receptor Agonist Market is projected to reach USD 7.38 billion in 2026 and is expected to continue growing at a CAGR of 13.31%, reaching USD 15.70 billion by 2032[reference:54].
Suppliers who can demonstrate large-scale SPPS capacity, advanced purification (RP-HPLC) capabilities, and robust quality systems are in high demand. The bottleneck currently lies in the availability of specialized production reactors and experienced personnel. In the first quarter of 2026, tirzepatide contributed US$12.822 billion in revenue to Eli Lilly, while semaglutide's global sales for the same period were approximately US$8.277 billion[reference:55].
To capitalize on this opportunity, peptide suppliers must invest in both infrastructure and R&D, particularly in developing oral formulations of GLP-1 peptides, which represent the next major frontier in this space. Partnerships between innovator companies and CDMOs are becoming increasingly strategic. The GLP-1 market has seen explosive growth in emerging markets as well—in India, the GLP-1 agonist market jumped from Rs 121 crore to Rs 1,736 crore in four years, with tirzepatide accounting for nearly 78% of the injectable GLP-1 market value[reference:56].
The expansion of GLP-1 drugs into newly approved health conditions points to a growing role across chronic diseases[reference:57]. As more providers and patients adopt GLP-1s for multiple conditions, the drug class is becoming relevant to a broader range of long-term health needs. GLP-1 use surged in 2025 and will grow as the drugs expand beyond diabetes and weight loss into cardiovascular, kidney, liver disease, sleep apnea, and other indications in development[reference:58].
For peptide suppliers, this trend means securing long-term supply agreements with pharmaceutical companies and investing in capacity expansion. The market is also seeing increased interest from generic manufacturers as patents expire, creating additional demand for peptide API production. Companies that can offer both innovative and generic peptide manufacturing capabilities will be best positioned to capture value across the GLP-1 value chain.